16 Dezember 2019

Alex Michine, CEO of MetGen, is the Most Innovative Bioeconomy CEO 2019

Alex Michine succeeds to Ken Richards (Leaf Resources), Tony Duncan (Circa Group) and Jürgen Eck, respectively most innovative CEO 2016, 2017 and 2018

The results

The results

Our readers have voted. The Blog has really seen a boom in visits.  The most innovative bioeconomy CEO 2019 is Alex Michine, CEO of MetGen, the Finnish company founded in 2008 and focused on genetic engineering and synthetic biology (you can read our recent interview with him here). Alex Michine succeeds to Ken Richards (Leaf Resources), Tony Duncan (Circa Group) and Jürgen Eck, respectively most innovative CEO 2016, 2017 and 2018.

We heartily congratulate him on this important recognition and sincerely thank our readers for the great participation in the survey. As usual, we would like to underline that the bioeconomy revolution is a reality thanks to visionary managers like Michine , the other nine selected along with him in the list of the 10 most innovative bioeconomy CEOs and to all those who in different roles contribute to research, develop and commercialize new bio-based products.

Alex Michine, CEO MetGen, with the Frost & Sullivan Award in London. Now a new award for him

Alex Michine, CEO MetGen, with the Frost & Sullivan Award in London. Now a new award for him

About the winner:

Alex Michine is a founder and CEO of MetGen since 2008. A serial entrepreneur, Alex has over 15 years of international experience in biotechnology, pharmaceutical and cleantech industries. He also serves on the Board of Directors of HyTest (Finland), a leading supplier of reagents for the in-vitro diagnostic market. Alex received his MBA from the Robert Kennedy College, Switzerland in 2005.
He was previously Founder and CEO of Metkinen (2002-2005), a company active in development of fermentation technologies for pharmaceutical market, and Founder and CEO of Metkinen Chemistry (2005-2008), a producer of reagents for RNA and DNA synthesis. Both previous companies are profitable and grew without external financing.

In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Nullam dictum felis eu pede mollis pretium. Integer tincidunt. Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet.

Powered by:

Source: Il Bioeconomista, 2019-12-10.

Supplier

Share on Twitter+1Share on FacebookShare on XingShare on LinkedInShare via email